Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Ugandan
100%
HIV-negative
100%
Cytopathology
100%
Human Papillomavirus Prevalence
100%
Liquid-like
100%
HIV-positive Women
75%
HPV Prevalence
75%
Risk Factors
50%
HPV Infection
50%
High-risk HPV
50%
HPV Genotyping
50%
Young Women
25%
Vaccine Effectiveness
25%
Genotype
25%
HIV Infection
25%
Public Health Risk
25%
HIV Status
25%
Multivariate Analysis
25%
Co-infection
25%
HPV Vaccine
25%
HIV-positive
25%
Developing World
25%
Collection Device
25%
Postpartum Women
25%
Cytological Samples
25%
HIV Prevalence
25%
Local Studies
25%
Cervical Dysplasia
25%
Kampala Uganda
25%
Cervical Neoplasia
25%
Pelvic Examination
25%
HPV18
25%
Abnormal Cervical Cytology
25%
Abnormal Cytology
25%
Liquid-based Cervical Cytology
25%
HPV-16/18
25%
DNA Collection
25%
Manual Technique
25%
Rapid HIV Testing
25%
HPV DNA
25%
Medicine and Dentistry
Health Care Cost
100%
Human Immunodeficiency Virus
100%
Prevalence
100%
Wart Virus
100%
Cytopathology
100%
Negative Woman
27%
Infection
18%
Uterine Cervix Cytology
18%
Cytotechnology
9%
Human Immunodeficiency Virus Infection
9%
Neoplasm
9%
Public Health
9%
HIV Test
9%
DNA A
9%
Human Papillomavirus Type 16
9%
Mixed Infection
9%
Uterine Cervix Dysplasia
9%
Pelvic Examination
9%
Human Papillomavirus Type 18
9%
Vaccine Efficacy
9%
Multivariate Analysis
9%
Immunology and Microbiology
Human Immunodeficiency Virus
100%
Prevalence
100%
Wart Virus
100%
Cytotechnology
25%
Cytology
25%
Cell Biology
25%
Infection
16%
Vaccine Efficacy
8%
Human Immunodeficiency Virus Infection
8%
Coinfection
8%
Human Papillomavirus Type 16
8%
HPV Vaccine
8%
Human Papillomavirus Type 18
8%
Pelvis
8%
Nursing and Health Professions
Human Immunodeficiency Virus
100%
Prevalence
100%
Infection
18%
Uterine Cervix Cytology
18%
HPV Vaccine
9%
Cytology
9%
Human Immunodeficiency Virus Infection
9%
HIV Test
9%
Vaccine Efficacy
9%
Mixed Infection
9%
Uterine Cervix Dysplasia
9%
Neoplasm
9%
Pelvic Examination
9%
DNA A
9%
Public Health
9%
Developing Country
9%
Multivariate Analysis
9%